Mazdutide

Synonyms: BI 456906, GLP-1/Glucagon receptor agonist, 2259884-03-0

Mazdutide is a synthetic peptide dual agonist targeting both the glucagon-like peptide-1 (GLP-1) and glucagon receptors. Developed by Innovent Biologics in partnership with Eli Lilly, it is currently in clinical development for the treatment of type 2 diabetes and obesity. The peptide combines the glucose-lowering effects of GLP-1 with the energy-expending effects of glucagon, offering a promising approach to addressing metabolic disorders.

Najważniejsze cechy produktu

• Dual agonist activity: Simultaneously activates GLP-1 and glucagon receptors for enhanced metabolic benefits.
• High purity: ≥98% as determined by HPLC, ensuring reliable and reproducible results.
• Research-grade quality: Manufactured under strict quality control, with comprehensive COA and MSDS provided.
• Custom packaging: Available in various sizes to meet different research needs.
• Pomoc techniczna: Our team of experts is available to assist with any questions regarding handling or storage.

Zastosowania

• Metabolic disease research, including type 2 diabetes and obesity.
• Studies on GLP-1 and glucagon receptor signaling pathways.
• Development of novel therapeutic peptides for metabolic disorders.

Dane techniczne

Zamówienia i dostawy

• Opakowanie: 5 g, 10 g, 50 g, 100 g, or customized
• MOQ: 5 g
• Czas realizacji: 1-2 weeks after order confirmation
• Dokumentacja: COA, MSDS, TDS provided

Zapytanie ofertowe

• Nasz adres: 280 Main Street, Xi’an, Shaanxi, Chiny
• LyvBio Sp. z o.o. — E-mail: info@lyvbio.com